K+ channels in the heart: New insights and therapeutic implications

Expert Review of Clinical Pharmacology

Volumn 3, Issue 3, 2010, Pages 305-319

  Tinker, Andrew ^a   Harmer, Stephen C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Arrhythmia; Atrial fibrillation; I Kur (Kv1.5); IKACh (Kir3.1 3.4); K+ channel

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; AVE 00118; CALCIUM CHANNEL L TYPE; DOFETILIDE; DRONEDARONE; ENCAINIDE; FLECAINIDE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; INAKALANT; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR3.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR3.4; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MORACIZINE; NIP 151; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE2; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KV1.4; POTASSIUM CHANNEL KV1.5; SHAL POTASSIUM CHANNEL; SOTALOL; SULFONYLUREA RECEPTOR 1; UNCLASSIFIED DRUG; VERNAKALANT; XEN D 0101;

CARDIOVERSION; CHANNEL GATING; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART AUTOMATICITY; HEART MUSCLE EXCITABILITY; HEART MUSCLE POTENTIAL; HEART PACING; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LONG QT SYNDROME; LOW DRUG DOSE; LUNG DISEASE; NONHUMAN; QT PROLONGATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM CURRENT; SUDDEN DEATH; THYROID DISEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

EID: 77952573270     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.14     Document Type: Review

References (147)

1. Noble D. The surprising heart: a review of recent progress in cardiac electrophysiology. J. Physiol. (Lond.) 353, 1-50 (1984).
2. + channels nets yet more diversity. Neuron 15, 489-492 (1995).
3. Jan LY, Jan YN. Cloned potassium channels from eukaryotes and prokaryotes. Annu. Rev. Neurosci. 20, 91-123 (1997).
4. Gouaux E, MacKinnon R. Principles of selective ion transport in channels and pumps. Science 310, 1461-1465 (2005).
5. + channel in a lipid membrane-like environment. Nature 450, 376-382 (2007).
6. Noseworthy PA, Newton-Cheh C. Genetic determinants of sudden cardiac death. Circulation 118, 1854-1863 (2008).
7. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114, e257-e354 (2006).
8. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol. Rev. 85, 1205-1253 (2005).
9. Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc. Res. 62, 9-33 (2004).
10. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415, 219-226 (2002).
11. Baruscotti M, Robinson RB. Electrophysiology and pacemaker function of the developing sinoatrial node. Am. J. Physiol. Heart Circ. Physiol. 293, H2613-H2623 (2007).
12. ATP) current in cultured neonatal rat atrial appendage cardiomyocytes. Circ. Res. 85, 707-715 (1999).
13. ATP channels require SUR1. Circ. Res. 103, 1458-1465 (2008).
14. + channel in ventricular muscle. A molecular correlate for the transient outward current. Circ. Res. 79, 659-668 (1996).
15. An WF, Bowlby MR, Betty M et al. Modulation of A-type potassium channels by a family of calcium sensors. Nature 403, 553-556 (2000).
16. v4.3 voltage-dependent gating kinetics by KChIP2 isoforms. J. Physiol. 557, 19-41 (2004).
17. v4-family transient potassium channels. Physiol. Rev. 84, 803-833 (2004).
18. + channels altered by presence of β-subunit. Nature 369, 289-294 (1994).
19. v1.4. J. Physiol. 509 (Pt 1), 171-182 (1998).
20. Gaborit N, Le BS, Szuts V et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J. Physiol. 582, 675-693 (2007).
21. + current similar to Kv1.5 cloned channel currents. Circ. Res. 73, 1061-1076 (1993).
22. v channel α/β subunit interactions. Trends Cardiovasc. Med. 9, 253-258 (1999).
23. v1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin. Investig. Drugs 18, 399-416 (2009).
24. Kr) channels. J. Biol. Chem. 275, 5997-6006 (2000).
25. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97, 175-187 (1999).
26. Ks) pore demonstrates two MinK subunits in each channel complex. Neuron 40, 15-23 (2003).
27. Ks) potassium channel. Nature 384, 80-83 (1996).
28. Ks) cardiac potassium current. Nature 384, 78-80 (1996).
29. Schram G, Pourrier M, Melnyk P, Nattel S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ. Res. 90, 939-950 (2002).
30. K1). J. Mol. Cell. Cardiol. 33, 625-638 (2001).
31. K1)) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. J. Physiol 533, 697-710 (2001).
32. + channels from guinea-pig cardiomyocytes. J. Physiol. 532, 115-126 (2001).
33. Noma A, Trautwein W. Relaxation of the ACh-induced potassium current in the rabbit sinoatrial node cell. Pflügers Archiv. 377, 193-200 (1978).
34. + channel: expression cloning and molecular properties. Proc. Natl Acad. Sci. USA 90, 10235-10239 (1993).
35. Kubo Y, Reuveny E, Slesinger PA, Jan YN, Jan LY. Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature 364, 802-806 (1993).
36. +) -channel proteins. Nature 374, 135-141 (1995).
37. Wickman K, Nemec J, Gendler SJ, Clapham DE. Abnormal heart rate regulation in Girk4 knockout mice. Neuron 20, 103-114 (1998).
38. Zingman LV, Alekseev AE, Hodgson-Zingman DM, Terzic A. ATP-sensitive potassium channels: metabolic sensing and cardioprotection. J. Appl. Physiol. 103, 1888-1893 (2007).
39. Yutzey KE, Robbins J. Principles of genetic murine models for cardiac disease. Circulation 115, 792-799 (2007).
40. + current modulates repolarization and excitation-contraction coupling in adult mouse ventricle. J. Physiol. 504 (Pt 3), 557-563 (1997).
41. + currents in adult mouse ventricles. J. Physiol. 559, 103-120 (2004).
42. Nerbonne JM. Studying cardiac arrhythmias in the mouse - a reasonable model for probing mechanisms? Trends Cardiovasc. Med. 14, 83-93 (2004).
43. + channel signature sequence. Biophys. J. 66, 1061-1067 (1994).
44. Aldrich RW. Fifty years of inactivation. Nature 411, 643-644 (2001).
45. Bezanilla F. How membrane proteins sense voltage. Nat. Rev. Mol. Cell Biol. 9, 323-332 (2008).
46. MacKinnon R. Potassium channels and the atomic basis of selective ion conduction (Nobel lecture). Angew. Chem. Int. Ed. Engl. 43, 4265-4277 (2004).
47. Tombola F, Pathak MM, Isacoff EY. How does voltage open an ion channel? Annu. Rev. Cell Dev. Biol. 22, 23-52 (2006).
48. Nichols CG, Makhina EN, Pearson WL, Sha Q, Lopatin AN. Inward rectification and implications for cardiac excitability. Circ. Res. 78, 1-7 (1996).
49. + (GIRK4) channel homomultimers. J. Biol. Chem. 273, 27499-27504 (1998).
50. Fleischmann BK, Duan Y, Fan Y et al. Differential subunit composition of the G protein-activated inward-rectifier potassium channel during cardiac development. J. Clin. Invest. 114, 994-1001 (2004).
51. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol. 61, 337-362 (1999).
52. Rodrigo GC, Standen NB. ATP-sensitive potassium channels. Curr. Pharm. Des. 11, 1915-1940 (2005).
53. + channel channel/enzyme multimer: metabolic gating in the heart. J. Mol. Cell. Cardiol. 38, 895-905 (2005).
54. Lesage F, Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels Am. J. Physiol. Renal Physiol. 279, F793-F801 (2000).
55. Putzke C, Wemhoner K, Sachse FB et al. The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc. Res. 75, 59-68 (2007).
56. Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ. Res. 74, 1071-1096 (1994).
57. Luo CH, Rudy Y. A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction. Circ. Res. 68, 1501-1526 (1991).
58. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc. Res. 42, 477-489 (1999).
59. + currents in repolarization. Circ. Res. 82, 63-81 (1998).
60. 2+ current. Circ. Res. 64, 977-990 (1989).
61. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 84, 1831-1851 (1991).
62. 2+) release causes myocyte depolarization. Underlying mechanism and threshold for triggered action potentials. Circ. Res. 87, 774-780 (2000).
63. Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc. Med. 14, 61-66 (2004).
64. Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 101, 194-199 (2000).
65. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Eur. Heart J. 12, 1112-1131 (1991).
66. Colatsky TJ, Argentieri TM. Potassiun channel blockers as antiarrhythmic drugs. Drug Dev. Res. 33, 235-249 (1994).
67. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2, 439-447 (2003).
68. Nattel S, Carlsson L. Innovative approaches to antiarrhythmic drug therapy. Nat. Rev. Drug Discov. 5, 1034-1049 (2006).
69. Nattel S, Maguy A, Le BS, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol. Rev. 87, 425-456 (2007).
70. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321, 406-412 (1989).
71. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N. Engl. J. Med. 327, 227-233 (1992).
72. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-sotalol. Lancet 348, 7-12 (1996).
73. Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with leftventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial investigators. Lancet 349, 667-674 (1997).
74. Moss AJ, Kass RS. Long QT syndrome: from channels to cardiac arrhythmias. J. Clin. Invest. 115, 2018-2024 (2005).
75. Huang L, Bitner-Glindzicz M, Tranebjaerg L, Tinker A. A spectrum of functional effects for disease causing mutations in the Jervell and Lange-Nielsen syndrome. Cardiovasc. Res. 51, 670-680 (2001).
76. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc. Natl Acad. Sci. USA 97, 12329-12333 (2000).
77. Akar FG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 105, 1247-1253 (2002).
78. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103, 2004-2013 (2001).
79. Hondeghem LM. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct. Eur. J. Pharmacol. 584, 1-9 (2008).
80. + current by dofetilide. Circ. Res. 72, 75-83 (1993).
81. Nakashima H, Gerlach U, Schmidt D, Nattel S. In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc. Res. 61, 705-714 (2004).
82. Chen YH, Xu SJ, Bendahhou S et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299, 251-254 (2003).
83. Xia M, Jin Q, Bendahhou S et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem. Biophys. Res. Commun. 332, 1012-1019 (2005).
84. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J. Cardiovasc. Electrophysiol. 16, 394-396 (2005).
85. Yang Y, Xia M, Jin Q et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am. J. Hum. Genet. 75, 899-905 (2004).
86. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
87. Van G, I, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834-1840 (2002).
88. Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N. Engl. J. Med. 352, 1861-1872 (2005).
89. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968 (1995).
90. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ. Res. 81, 512-525 (1997).
91. + current in a chronic dog model of atrial fibrillation. Circ. Res. 81, 1045-1052 (1997).
92. v1.5 expression are reduced in chronic human atrial fibrillation. Circ. Res. 80, 772-781 (1997).
93. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ. Res. 84, 776-784 (1999).
94. K, ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation 104, 2551-2557 (2001).
95. K, ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 112, 3697-3706 (2005).
96. Xiao L, Xiao J, Luo X, Lin H, Wang Z, Nattel S. Feedback remodeling of cardiac potassium current expression: a novel potential mechanism for control of repolarization reserve. Circulation 118, 983-992 (2008).
97. Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am. Heart J. 157, 243-252 (2009).
98. Norgaard BL, Wachtell K, Christensen PD et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am. Heart J. 137, 1062-1069 (1999).
99. Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med. 341, 857-865 (1999).
100. Roukoz H, Saliba W. Dofetilide: a new class III antiarrhythmic agent. Expert Rev. Cardiovasc. Ther. 5, 9-19 (2007).
101. Allen MJ, Nichols DJ, Oliver SD. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br. J. Clin. Pharmacol. 50, 247-253 (2000).
102. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current antiarrhythmic drugs, investigational agents, and innovative approaches. Europace 10, 647-665 (2008).
103. Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J. Cardiovasc. Pharmacol. 41, 191-202 (2003).
104. + current in guinea pig atrial cells. J. Cardiovasc. Pharmacol. 36, 802-805 (2000).
105. Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357, 987-999 (2007).
106. Hohnloser SH, Crijns HJ, van EM et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668-678 (2009).
107. Kober L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358, 2678-2687 (2008).
108. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol. 54, 1089-1095 (2009).
109. Kur promote atrial fibrillation? Heart Rhythm 5, 1304-1309 (2008).
110. Roy D, Pratt CM, Torp-Pedersen C et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a Phase 3, randomized, placebo-controlled trial. Circulation 117, 1518-1525 (2008).
111. v1.5 channels. Mol. Pharmacol. 72, 1522-1534 (2007).
112. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin. Investig. Drugs 16, 519-532 (2007).
113. Crijns HJ, Van GI, Walfridsson H et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 3, 1321-1331 (2006).
114. Blaauw Y, Gogelein H, Tieleman RG, van HA, Schotten U, Allessie MA. 'Early' class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110, 1717-1724 (2004).
115. DE Vos CB, Nieuwlaat R, Crijns HJ et al. Autonomic trigger patterns and antiarrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur. Heart J. 29, 632-639 (2008).
116. Coumel P, Attuel P, Lavallee J, Flammang D. The atrial arrhythmia syndrome of vagal origin. Arch. Mal. Coeur Vaiss. 71, 645-656 (1978).
117. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 105, 2753-2759 (2002).
118. Sharifov OF, Fedorov V V, Beloshapko GG, Glukhov AV, Yushmanova AV, Rosenshtraukh LV. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J. Am. Coll. Cardiol. 43, 483-490 (2004).
119. Pappone C, Santinelli V, Manguso F et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 109, 327-334 (2004).
120. Yamada M, Inanobe A, Kurachi Y. G protein regulation of potassium ion channels. Pharmacol. Rev. 50, 723-757 (1998).
121. K, ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovasc. Res. 7 7, 35-43 (2008).
122. K, ACh channels in patients with chronic atrial fibrillation. Cardiovasc. Res. 74, 426-437 (2007).
123. 2+-independent protein kinase C. J. Physiol. (Lond.) 534, 367-379 (2001).
124. +) channels in rabbit cardiac myocytes. J. Pharmacol. Exp. Ther. 293, 196-205 (2000).
125. KACh) in acetylcholine-induced atrioventricular blocks. Br. J. Pharmacol. 131, 569-577 (2000).
126. + channels. Biochemistry 38, 14286-14293 (1999).
127. + channels in a use-dependent manner. J. Pharmacol. Exp. Ther. 314, 1353-1361 (2005).
128. Kr-blocker dofetilide. J. Cardiovasc. Pharmacol. 51, 162-169 (2008).
129. Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Annu. Rev. Pharmacol. Toxicol. 33, 597-637 (1993).
130. ATP) channels. Diabetes 47, 1412-1418 (1998).
131. ATP) channels to gliclazide. Diabetologia 42, 845-848 (1999).
132. Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Differential interactions of nateglinide and repaglinide on the human β-cell sulphonylurea receptor 1. Diabetes 51, 2789-2795 (2002).
133. Zingman LV, Hodgson DM, Bast PH et al. Kir6.2 is required for adaptation to stress. Proc. Natl Acad. Sci. USA 99, 13278-13283 (2002).
134. + channel, predisposes to catecholamineinduced ventricular dysrhythmia. Diabetes 53 (Suppl. 3), S165-S168 (2004).
135. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev. 83, 1113-1151 (2003).
136. O'Rourke B. Mitochondrial ion channels. Annu. Rev. Physiol 69, 19-49 (2007).
137. Chi L, Uprichard AC, Lucchesi BR. Profibrillatory actions of pinacidil in a conscious canine model of sudden coronary death. J. Cardiovasc. Pharmacol. 15, 452-464 (1990).
138. Kerr MJ, Wilson R, Shanks RG. Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug. J. Cardiovasc. Pharmacol. 7, 875-883 (1985).
139. +) current density during chronic human atrial fibrillation. J. Mol. Cell. Cardiol. 35, 1399-1405 (2003).
140. Arking DE, Pfeufer A, Post W et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat. Genet. 38, 644-651 (2006).
141. Pfeufer A, Sanna S, Arking DE et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat. Genet. 41, 407-414 (2009).
142. Newton-Cheh C, Eijgelsheim M, Rice KM et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat. Genet. 41, 399-406 (2009).
143. Chang KC, Barth AS, Sasano T et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc. Natl Acad. Sci. USA 105, 4477-4482 (2008).
144. Gudbjartsson DF, Arnar DO, Helgadottir A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448, 353-357 (2007).
145. Kaab S, Darbar D, van NC et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur. Heart J. 30, 813-819 (2009).
146. Gudbjartsson DF, Holm H, Gretarsdottir S et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat. Genet. 41, 876-878 (2009).
147. Benjamin EJ, Rice KM, Arking DE et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat. Genet. 41, 879-881 (2009).